Allergy Therapeutics (LON:AGY) Hits New 12-Month Low – Here’s What Happened

Shares of Allergy Therapeutics plc (LON:AGY) reached a new 52-week low during trading on Wednesday . The stock traded as low as GBX 6.50 and last traded at GBX 7.50, with a volume of 203060 shares. The stock had previously closed at GBX 7.50.

Allergy Therapeutics Stock Performance

The company has a quick ratio of 1.48, a current ratio of 1.13 and a debt-to-equity ratio of 629.58. The company has a market capitalization of £474.94 million, a price-to-earnings ratio of -7.73, a P/E/G ratio of -30.70 and a beta of 0.89. The company has a 50-day moving average price of GBX 9.75 and a 200-day moving average price of GBX 10.56.

Allergy Therapeutics (LON:AGY) last posted its quarterly earnings data on Tuesday, March 31st. The company reported GBX (0.38) earnings per share for the quarter. The business had revenue of GBX 3,628 million during the quarter. Allergy Therapeutics had a negative net margin of 85.46% and a positive return on equity of 409.00%. Research analysts predict that Allergy Therapeutics plc will post -2.56 EPS for the current fiscal year.

Allergy Therapeutics Company Profile

Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development.